Efficacy , safety and tolerability of Atorvastatin 40 mg in patients with relapsing remitting multiple sclerosis in treatment with interferon-beta-(ARIANNA) – Multicenter, randomised, double blind, placebo controlled, parallel-group-study. Studio Schering – prot. DR04-07-02.
An active extension of LAQ/5062 study – multinational, multi-center, randomised, double-blind, parallel-group study, to evacuate the safety, tolerability and efficacy of two doses (0.3mg and 0.6mg) of laquinimod, orally administered in relapsing-remitting (R-R) multiple sclerosis (MS) subjects. Teva Pharmaceutical Industries. Prot. N. LAQ/5063
FORTE – GA/9016 A multinational, multicenter, randomized, parallel-group, double-blind study, to compare the efficacy, tollerabilità and safety of glatiramer acetate injection 40mg/ml to rhat of glatiramer acetate injection 20 mg/ml administered once daily by subcutaneous injection in subjects with relapsing remitting (R-R) multiple sclerosis (MS)
Multicenter. Open-label, 12 weeks Phase IV study to assess adherence to treatment in relapsing multiple sclerosis (RMS) subjects switching from othr injectable DMDs using ReBiSmart to self-inject Rebif New Formulation (RNF) In a multi-dose cartriDGE – BRIDGE – Merck Serono prot. 701048-525
A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 1,25 mg FTY20 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis. Novartis Pharma, prot. CFTY720D2306